What happened
Novartis and Ionis reported topline Phase III results from Lp(a)HORIZON on September 4: 8,323 patients with elevated Lp(a) and established cardiovascular disease on guideline-directed therapy. Pelacarsen lowered Lp(a) as expected. It did not reduce the composite of CV death, MI, stroke, or urgent revascularization versus placebo, in either the 70 mg/dL or the 90 mg/dL population.
What it means for practice
one trial, one population, one dose. The Lp(a) hypothesis is still alive, and the deeper-lowering programs will tell us more. For now, measuring Lp(a) still changes how you counsel residual risk, and that was always the reason to measure it.
Originally published in The Longevity Medicine Intelligence newsletter (#105).
WRITTEN BYlongevitydocs™ editorsCurated by the longevitydocs™ editorial team from the weekly newsletter
